Data Insights

Dupilumab by Regeneron Pharmaceuticals for Alopecia Areata: Likelihood of Approval

Dupilumab is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Alopecia Areata. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Dupilumab in Alopecia Areata

Data Insights

Dupilumab by Regeneron Pharmaceuticals for Keloids: Likelihood of Approval

Dupilumab is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Keloids. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Dupilumab in Keloids

Data Insights

Dupilumab by Regeneron Pharmaceuticals for Immunoglobulin G4-Related Disease (IgG4-RD): Likelihood of Approval

Dupilumab is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Immunoglobulin G4-Related Disease (IgG4-RD). According to...

Likelihood of Approval and Phase Transition Success Rate Model - Dupilumab in Immunoglobulin G4-Related Disease (IgG4-RD)

Data Insights

Dupilumab by Regeneron Pharmaceuticals for Non-Small Cell Lung Cancer: Likelihood of Approval

Dupilumab is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Non-Small Cell Lung Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Dupilumab in Non-Small Cell Lung Cancer

Data Insights

Dupilumab by Regeneron Pharmaceuticals for Gastritis: Likelihood of Approval

Dupilumab is under clinical development by Regeneron Pharmaceuticals and currently in Phase III for Gastritis. According to GlobalData, Phase III...

Likelihood of Approval and Phase Transition Success Rate Model - Dupilumab in Gastritis

Data Insights

Dupilumab by Regeneron Pharmaceuticals for Gastroenteritis: Likelihood of Approval

Dupilumab is under clinical development by Regeneron Pharmaceuticals and currently in Phase III for Gastroenteritis. According to GlobalData, Phase III...

Likelihood of Approval and Phase Transition Success Rate Model - Dupilumab in Gastroenteritis

Data Insights

Dupilumab by Regeneron Pharmaceuticals for Bullous Pemphigoid: Likelihood of Approval

Dupilumab is under clinical development by Regeneron Pharmaceuticals and currently in Phase III for Bullous Pemphigoid. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Dupilumab in Bullous Pemphigoid

Data Insights

Dupilumab by Regeneron Pharmaceuticals for Systemic Sclerosis (Scleroderma): Likelihood of Approval

Dupilumab is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Systemic Sclerosis (Scleroderma). According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Dupilumab in Systemic Sclerosis (Scleroderma)

Data Insights

Dupilumab by Regeneron Pharmaceuticals for Chronic Obstructive Pulmonary Disease (COPD): Likelihood of Approval

Dupilumab is under clinical development by Regeneron Pharmaceuticals and currently in Pre-Registration for Chronic Obstructive Pulmonary Disease (COPD). According to...

Likelihood of Approval and Phase Transition Success Rate Model - Dupilumab in Chronic Obstructive Pulmonary Disease (COPD)